Search form

Scroll To Top

food and drug administration

CVS pharmacy window customer interaction
Health

CVS Health denies coverage for  breakthrough HIV drug, committing 'clear violation' of ACA

CVS Health will not cover Gilead's Yeztugo, generic name lenacapavir (LEN), citing "clinical, financial, and regulatory factors."

​The Food and Drug Administration has approved lenacapavir, a breakthrough medication that reduces the risk of contracting HIV by 96 percent
Health

FDA approves breakthrough drug that reduces risk of contracting HIV by 96 percent

Otherwise known by its generic name lenacapavir (LEN), Yeztugo has been approved after nearly eliminating the spread of HIV among trial patients.